Cenix BioScience GmbH

Tatzberg 47
01307 Dresden

Phone: +49 (351) 41730
Fax: +49 (351) 4173109


Cenix BioScience GmbH is a pioneer and global leader in the convergence of high throughput (HT), genomics-driven applications of RNA interference (RNAi) with high content, multi-parametric cell-based assays. Founded in 1999 as the first biotechnology company specializing in HT-RNAi, Cenix has accumulated unparalleled depth and breadth of experience in this field, using human and rodent cell models in a wide range of disease indications, including oncology, atherosclerosis, diabetes, obesity, neurodegenerative disorders and infectious diseases such as malaria. Cenix offers its unique expertise to industry and academic partners through fully customizable research services, focusing on the discovery and validation of novel therapeutic drug targets and the analysis of drug mechanisms of action.